Analyzing Anika Therapeutics (ANIK) & Its Peers
Anika Therapeutics (NASDAQ: ANIK) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its rivals? We will compare Anika Therapeutics to similar businesses based on the strength of its earnings, institutional ownership, profitability, risk, analyst recommendations, dividends and valuation.
Earnings and Valuation
This table compares Anika Therapeutics and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Anika Therapeutics||$111.36 million||$56.02 million||26.30|
|Anika Therapeutics Competitors||$579.30 million||$241.72 million||-6.68|
Anika Therapeutics’ rivals have higher revenue and earnings than Anika Therapeutics. Anika Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Anika Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anika Therapeutics Competitors||-13,401.00%||218.39%||-20.55%|
Risk & Volatility
Anika Therapeutics has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Anika Therapeutics’ rivals have a beta of 1.28, meaning that their average share price is 28% more volatile than the S&P 500.
Insider & Institutional Ownership
84.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 6.6% of Anika Therapeutics shares are held by insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a summary of current ratings and recommmendations for Anika Therapeutics and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anika Therapeutics Competitors||194||914||1695||67||2.57|
As a group, “Biopharmaceuticals” companies have a potential upside of 7.36%. Given Anika Therapeutics’ rivals higher probable upside, analysts clearly believe Anika Therapeutics has less favorable growth aspects than its rivals.
Anika Therapeutics Company Profile
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.